TrialHaematologica2017

Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study.

Gilles Salles et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.